Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HIV Infections: early-phase trial registry
56 of 615 indexed HIV Infections trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7 of 28,707 conditions by registered trial count.
615 US clinical trials · 56 currently recruiting · #7 of 28,707 conditions by registered trial count
HIV Infections: 615 US clinical trials tracked, 56 recruiting.
HIV Infections is the subject of 615 registered US clinical trials on ClinicalTrials.gov, 56 of them currently open to new participants. 92 are in Phase 3-4 (later-stage) and 266 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 195 of these trials.
Enrollment posture brief
Registry condition hiv-infections
OPEN 56 | RECR 9% | LATE 92 | EARLY 266 | RANK #7 | SPON 195
Volume-matched condition peers
Nearest open-share peer: Acute Lung Injury (9% recruiting · 11 trials)
HIV Infections lists 56 open slots (9% of 615 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HIV Infections on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HIV Infections is recruiting below its size-band peers.
56 of 615 indexed trials (9.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates HIV Infections research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 195 of 615 trials (31.7%). 173 distinct sponsors appear on at least one study for this condition label.
-
Typical HIV Infections enrolment sits around 100 participants.
Median target enrolment is 100 among the 543 trials that report a genuine target (sentinel values excluded). 267 of those (49.2%) plan for fewer than 100 participants.
-
HIV Infections research is mostly interventional.
549 interventional and 66 observational studies make up this index (89.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
615 total, page 5 of 13
The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease
Boehringer Ingelheim
NCT00002324
A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000658
A "Pre-Enrollment" Protocol for HIV-Infected Adolescents
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000780
Metabolic Abnormalities - HIV Infected and Uninfected Males
University of North Carolina, Chapel Hill
NCT00260936
Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine
ViiV Healthcare
NCT01641809
A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral/Oral Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia in AIDS
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000715
Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000665
Anti-HIV Drug Regimens With or Without Protease Inhibitors and Drug Level Monitoring in HIV Infected Adolescents
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00075907
A Network Intervention for Reducing Sexual Risk for HIV With African American Men Who Have Sex With Men (AA MSM)
Centers for Disease Control and Prevention
NCT00691041
A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients
Glaxo Wellcome
NCT00005106
A Randomized, Comparative Trial of Zidovudine (AZT) Versus 2',3'-Didehydro-3'-Deoxythymidine (Stavudine; d4T) in Children With HIV Infection
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000789
Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma
Sequus Pharmaceuticals
NCT00002105
Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy
Pfizer's Upjohn has merged with Mylan to form Viatris
NCT00264875
Proyecto SOL: A Risk Reduction Intervention for Hispanic Men Who Have Sex With Men (MSM)
Centers for Disease Control and Prevention
NCT00690976
TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen
Centers for Disease Control and Prevention
NCT00023361
Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors
Glaxo Wellcome
NCT00002193
The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs
Glaxo Wellcome
NCT00002389
A Study of Disease Progression and Anti-HIV Treatments
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001068
Vitamin D Reabsorption in Adolescents and Young Adults With HIV Infection
University of North Carolina, Chapel Hill
NCT00490412
Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04518228
Enhancing HIV Prevention by Using Behavioral Intervention Among HIV-Infected Men
Fenway Community Health
NCT00231972
Motiv82Change: an HIV Prevention Study for Young Latino Men
Nova Southeastern University
NCT00877695
A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000870
A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
Bristol-Myers Squibb
NCT00002369
A Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients
Hoechst Marion Roussel
NCT00002150
Factors Affecting Adherence to Anti-HIV Drug Regimens in Children and Adolescents
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00073424
Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients
Bristol-Myers Squibb
NCT00084253
Identifying Emergency Room Patients Who Have Recently Been Infected With HIV
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001130
Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001091
A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS
Hoffmann-La Roche
NCT00002222
Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02178800
Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir
Bristol-Myers Squibb
NCT00120393
Tailored Motivational Interviewing Implementation-Effectiveness Trial in Multidisciplinary Adolescent HIV Care Settings
Florida State University
NCT03681912
Enhancing Communication and HIV Outcomes
Johns Hopkins University
NCT00675610
Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01302847
Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00071851
Pediatric Impact: Promoting Adherence to Medications Among HIV-infected Children
Centers for Disease Control and Prevention
NCT00134602
Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01095224
A Study of Didanosine Use Alone or in Combination With Zidovudine in Infants Exposed to or Infected With HIV
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001049
A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00076063
A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000755
Adherence and Acceptability to and Blood Levels of Tenofovir Gel and Tablets in HIV Uninfected Women
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00592124
Effects of Highly Active Anti-Retroviral Therapy on Cardiovascular Health in Infants of HIV-Infected Mothers
University of Miami
NCT00253682
Advancing HIV Prevention and Linkage to Care Among MSM With Gamification
University of California, Berkeley
NCT02946164
Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals
Boehringer Ingelheim
NCT00034866
OPTIONS: A Patient-Centered HIV Prevention Decision Aid for PrEP Uptake for Women With Substance Use in Treatment Settings
Yale University
NCT03651453
The Effects of Combination Anti-HIV Medication on Human Papillomavirus (HPV) in HIV-Infected Women
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00006444
Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients
Pharmacia and Upjohn
NCT00002211
A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000758
Physician Focused Intervention to Improve Adherence With HIV Antiretrovirals
National Institute on Drug Abuse (NIDA)
NCT00870792
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 157 |
| Phase 2 | 109 |
| Phase 3 | 69 |
| Phase 4 | 23 |
Top Sponsors
Named interventions
Most-linked intervention names on HIV Infections records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HIV Infections trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HIV Infections page
615 registered trials, 56 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 56 HIV Infections trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most HIV Infections trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HIV Infections condition card totals 615 registered trials; most-linked intervention Zidovudine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.